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Introduction {#sec001}
============

*Streptococcus pneumoniae* is a colonizing agent of the nasopharynx, and its dissemination to other body parts can cause pneumonia, meningitis, septicemia, otitis media, and sinusitis. Main targets for pneumococcal infections are children and the elderly over 65 years of age \[[@pone.0237247.ref001]--[@pone.0237247.ref003]\], especially in low income countries and in countries with low diagnosis and treatment \[[@pone.0237247.ref004]\]. The nasopharynx is the primary reservoir for pneumococci, and its carriage is the source of disease spread between people \[[@pone.0237247.ref005]\]. Although colonization of *S*. *pneumoniae* is mostly symptomless, it is considered as a prerequisite for transmission and progress of respiratory or even systemic disease \[[@pone.0237247.ref006]\]. Pneumococcal carriage is believed to be an important source of horizontal spread of this pathogen within the community \[[@pone.0237247.ref007]\]. *S*. *pneumoniae* was given the name as the forgotten killer in children in 2006 by the WHO \[[@pone.0237247.ref008]\], which accounts for more than one third of acute bacterial sinusitis and more than one half of community-acquired bacterial pneumonia \[[@pone.0237247.ref009]\]. For this reason, it is essential to determine the distribution of *S*. *pneumoniae* serotypes among children in each country in order to address the actual value of using available commercial vaccines to minimize the pneumococcal infections \[[@pone.0237247.ref010]\]. Vaccination proved to be effective against pneumococcal colonization, however, a simultaneous increase in colonization with non-vaccine serotypes was observed \[[@pone.0237247.ref011], [@pone.0237247.ref012]\]. As a result, new pneumococcal conjugate vaccines (PCVs) covering 15 and 20 different serotypes are planned as the future vaccines for 2020. Predisposing factors such as children below 5 years, elderly over 65 years of age and people with low immunity can increase the pneumococcal carriage \[[@pone.0237247.ref003], [@pone.0237247.ref007]\]. Furthermore, other socio-economic factors like crowding, low income families, smoking, viral respiratory infections, lack of pneumococcal vaccination and antibiotic consumption can affect pneumococcal colonization \[[@pone.0237247.ref013]\]. Pneumococcal carriage rates, pneumococcal conjugate vaccine coverage and resistance rates are variable world-wide depending on the use of vaccination, correct use of antibiotics, socio-economic factors, age and urban or rural residency of people \[[@pone.0237247.ref014]\]. To this point, NP-carriage rate in Japanese children zero to 6 years of age attending DCCs was 43.3% with penicillin intermediate resistance of 35.7% and erythromycin resistance of 69.4% \[[@pone.0237247.ref015]\]. However, carriage rate in Turkish infants up to two years of age was 22.5% with 6.8% high grade penicillin resistance and 59% PCV13 coverage \[[@pone.0237247.ref016]\]. Another study of carriage rate in malnourished children showed 77.8% carriage in infants 6--60 months of age \[[@pone.0237247.ref017]\]. Studies in countries with PCVs as part of the National Immunization Programs (NIP) showed an increase of non-vaccine serotypes and decrease of vaccine serotypes. In a study performed on children in Palestine, pneumococcal carriage rate was 55.7% with dominant serotypes 6A (13.6%) followed by 19F (12.2%) \[[@pone.0237247.ref018]\]. Similar results were seen in Gaza on healthy children and showed pneumococcal carriage rate of 50% and 46% coverage of PCV13 \[[@pone.0237247.ref019]\]. Jordan is a middle-income country with about 40% of the population below 15 years of age, which is considered as large target group for the dissemination of pneumococcal infections. Pneumococcal vaccines were introduced to Jordan in the year 2000 only in the private sector, but still not part of the NIP. DCCs chosen for this study are from rural areas with low to middle income and were all not vaccinated with the PCVs. Local information about the serotypes causing diseases in young children in Jordan is essential for future vaccination programs. Continous surveillance of pneumococcal carriage and resistance is essential for preventing pneumococcal multidrug resistant strains using the PCVs \[[@pone.0237247.ref020]\]. The objective of this study project is to find out the prevalence of carriage with *Streptococcus pneumoniae* in the winter seasons of the years 2017--2018, and 2018--2019 in children 2--4 years of age in two district regions of Jordan (eastern Irbid and 4 regions in Madaba), and find out the resistance rates of the isolates. Monitoring serotype distribution and determination of carriage and coverage rates of different PCVs are important criteria for appropriate application of the vaccines before introducing the PCVs into the NIP in Jordan.

Materials and methods {#sec002}
=====================

Ethics statement {#sec003}
----------------

The study was first approved by Independent Ethics Committee (IEC) from the Ministry of Health of Jordan followed by approval of the Ministry of Health of Jordan and approvals of each DCC director involved in this study. Informed written consent was obtained from parents of participating children, so that a parent of each child enrolled in the study gave written permission for a nasopharyngeal swab to be taken from their child and for relevant data to be used for protocoling. The parents were also educated on the benefits of the future vaccination with the available PCVs. Questionnaires with names, date of birth, gender, number of household, address, and history of PCV vaccination were recorded at the time of sample collection. All NP-samples were collected from trained medical doctors of each DCC. Positive results of carriage with resistance analysis and serotyping were sent to the medical doctors of each DCC to be registered on files of the participating children.

Study period and population involved {#sec004}
------------------------------------

Surveillance study of nasopharyngeal carriage and antibiotic resistance of *Streptococcus pneumoniae* in healthy Jordanian infants was launched in two main cities during two winter seasons in the period between October 2017 to the end of March 2018 and from October 2018 to the end of March 2019. The study was conducted on 1019 healthy children 2--4 years of age. Samples were collected from four DCCs of Madaba (East, west, north and south), and one DCC of eastern Irbid. All DCCs are found in rural areas with low to middle income families and the participating children have no history of PCV vaccination. The municipality of Madaba has a population of 82,335 inhabitants and for Irbid 307,480 inhabitants. Age group 2 to 4 years constitute of 6.6% of the total population of Jordan. All children coming to the day care centers (DCCs) for check-ups and for routine consultations in the age group 2--4 years were enrolled in this study. During the whole study period, a single nasopharyngeal swab was taken from each child. Duplicate swabs from the same child in different periods of the study were not considered.

Sampling and identification {#sec005}
---------------------------

Nasopharyngeal cotton swabs were collected as previously described \[[@pone.0237247.ref021]\]. Swabs were placed in Stuart transport media and were put in transport box for direct transport to the microbiology reference lab of the German Jordanian University. Samples were directly streaked on Columbia blood agar base supplemented with 5% sheep blood and incubated for 24 hours at 37°C with 5% CO~2~. Suspected α-haemolytic colonies were further tested for optochin sensitivity (bioMérieux) and bile solubility \[[@pone.0237247.ref022]--[@pone.0237247.ref024]\]. Positive isolates sensitive to optochin and bile soluble were frozen at -70°C for serotyping and antimicrobial sensitivity testing.

Capsular serotyping {#sec006}
-------------------

Pure cultures of *Streptococcus pneumoniae* incubated for 18--24 hours at 37°C with 5% CO~2~ were taken for serotyping by the Neufeld's Quellung reaction method using commercially available type and factor sera provided by the Statens Serum Institute, Copenhagen, Denmark \[[@pone.0237247.ref025]\].

Antimicrobial susceptibility testing {#sec007}
------------------------------------

Minimal inhibitory concentration (MIC) testing was performed using the micro broth dilution method with the VITEK2 compact system using cards AST03 for *Streptococcus pneumoniae*, and using E-tests obtained from Oxoid and bioMérieux. Antibiotics used were: Penicillin G (PEN), amoxicillin (AMOX), cefotaxime (CETA), cefuroxime (CEFU), cefpodoxim (CEPO), ceftriaxone, clarithromycin (CLA), clindamycin (CLI), tetracycline (TET), levofloxacin (LEVO), moxifloxacin, telithromycin, sulfamethoxazole-trimethoprim (SXT), chloramphenicole (CHA), vancomycin, tigecycline, linezolid, and rifampicin. *S*. *pneumoniae* ATCC 49619 was used as a control strain. Breakpoints for susceptibility used in this study were interpreted according to Clinical Laboratory Standards Institute (CLSI) guidelines \[[@pone.0237247.ref026]\].

Primary and secondary efficacy endpoints {#sec008}
----------------------------------------

This include the frequency of NP-carriage, serotype distribution and antimicrobial resistance patterns of the strains in children between 2--4 years of age. Although there is no true efficacy in this project, determination and assessment of the vaccine type pneumococcal carriage was determined. Furthermore, rates of resistant strains were documented.

Statistical analysis {#sec009}
--------------------

Student t-test was considered for significant differences using 2-tailed values with the level of significance at p\<0.05. Other analysis include: Rate of carriage, vaccine and non-vaccine serotype coverage, resistance rates to antibiotics, Analysis for age, sex, and seasonal variations.

Results {#sec010}
=======

The total number of NP-samples collected were 1019, where 530 (52.0%) were from male and 489 (48.0%) were from females. Male swabs were 40.2% from Irbid and 59.8% from Madaba DCCs, whereas female swabs were 42.9% from Irbid and 57.1% from Madaba DCCs ([Table 1](#pone.0237247.t001){ref-type="table"}).

10.1371/journal.pone.0237247.t001

###### Source of 1019 nasopharyngeal samples according to the gender in the winter seasons of 2017--2018 and 2018--2019.

![](pone.0237247.t001){#pone.0237247.t001g}

  City                 Male n (%)    Female n (%)   Total n (%)
  -------------------- ------------- -------------- -------------
  Easten Irbid         213 (40.2%)   210 (42.9%)    423 (41.5%)
  Madaba all regions   317 (59.8%)   279 (57.1%)    596 (58.5%)
  Total                530 (52.0%)   489 (48.0%)    1019 (100%)

Detailed number of NP-samples from each DCC and each season is presented in [S1 Table](#pone.0237247.s001){ref-type="supplementary-material"}.

All children enrolled in the study were in the age group 2 to 4 years and the average age of all children at the time of enrolment was 36.2 months. Total carriage rate in all centers for both cities and both seasons was 33.5%. A significant difference (*P*\< 0.05) was noticed for carriage in both seasons between Irbid (29.6%), and all DCCs of Madaba (36.2%). Gender significant difference (*P\< 0*.*05*) in the study was also noticed between male carriers of all centers of Madaba (41.6%) compared to male carriers (23.8%) from Irbid. Total carriage for females for all centers in Madaba was the same in both seasons (33.0%). Total carriage rate in Irbid in W2017-2018 (29.0%) was not significantly different from the carriage rate in the W2018-2019 (29.8%) (*P\< 0*.*05*). Detailed numbers of gender carriage for each center and each season are available in the supplementary data, (see [S2 Table](#pone.0237247.s002){ref-type="supplementary-material"}).

The average household measured in this study for eastern Irbid was 5.2 children for each family, whereas in Madaba was 3.6 children. Carriage rates for Irbid and Madaba for households with five or more children was shown to be 66.4% for Irbid, and 70.4% for Madaba. ([Table 2](#pone.0237247.t002){ref-type="table"}).

10.1371/journal.pone.0237247.t002

###### Carriage in Irbid and Madaba with household of \> = 5 or less than 5 children for both winter seasons.

![](pone.0237247.t002){#pone.0237247.t002g}

  Household         Carriage in Irbid   Carriage in Madaba             
  ----------------- ------------------- -------------------- --------- ------
  \> = 5 children   83/125              66.4                 152/216   70.4
  \< 5 children     42/125              33.6                 64/216    29.6

In both cities, carriage was significantly higher (*P\<0*.*05*) in the age group 2--3 years old children, which was 32.6% for Irbid and 38.1% for Madaba. Penicillin resistance in this age group has reached more than 96% in both cities, and that the coverage of PCV13 was 68.3% for Irbid and 65.5% for Madaba. Detailed numbers are available in supplementary file (see [S3 Table](#pone.0237247.s003){ref-type="supplementary-material"}).

On a monthly basis, pneumococcal carriage was highest among strains isolated in March (44.7%) for eastern Irbid, which was not significantly different (*P \> 0*.*05*) from those isolated from Madaba (45.5%) as shown in Figs [1](#pone.0237247.g001){ref-type="fig"} and [2](#pone.0237247.g002){ref-type="fig"}. Detailed numbers for Figs [1](#pone.0237247.g001){ref-type="fig"} and [2](#pone.0237247.g002){ref-type="fig"} are available in supplementary file (see [S4](#pone.0237247.s004){ref-type="supplementary-material"} and [S5](#pone.0237247.s005){ref-type="supplementary-material"} Tables). Coverage of PCV13, on the other hand, has reached 100% for strains isolated in November followed by 78.6% for strains isolated in January for eastern Irbid ([Fig 1](#pone.0237247.g001){ref-type="fig"}). The same highest coverage rate was noticed for the strains isolated in November for Madaba (78.9%) ([Fig 1](#pone.0237247.g001){ref-type="fig"}). With regard to the resistance rate on monthly basis for both regions, penicillin resistance was highest in the months from October to January (96.8%-100%) for eastern Irbid, but was highest in February (100%) for Madaba as shown in [Fig 2](#pone.0237247.g002){ref-type="fig"}. Furthermore, clarithromycin resistance reached 100% in November for Irbid followed by 90.9% in February, and that trimethoprim-sulfamethoxazole resistance was highest in isolates of November and December of the year with rates 96.8%-100%. As a comparison clarithromycin resistance was highest in isolates of January (87.8%), but trimethoprim-sulfamethoxazole resistance was highest in isolates of October (96.4%) for Madaba ([Fig 2](#pone.0237247.g002){ref-type="fig"}).

![Distribution of carriage and PCV13 coverage rates according to the month of isolation from Irbid and Madaba in both winter seasons.](pone.0237247.g001){#pone.0237247.g001}

![Resistance rates of pneumococcal isolates on monthly basis from eastern Irbid and Madaba in both winter seasons.\
Abbreviations: PEN (Penicillin), CLA (Clarithromycin), CLI (Clindamycin), SXT (Sulfamethoxazole-Trimethoprim), TET (Tetracycline), CHA (Chloramphenicol).](pone.0237247.g002){#pone.0237247.g002}

The overall rate of carriage for Madaba regions (36.2%) was significantly higher (*P \< 0*.*05*) than eastern Irbid (29.6%), however vaccine types of isolates from eastern Irbid were 66.4%, compared to 67.1% for all regions of Madaba, although southern region of Madaba showed the highest coverage of 73.2% ([Table 3](#pone.0237247.t003){ref-type="table"}). Differences in carriage of *Streptococcus pneumoniae* isolates from each DCC of Madaba regions showed highest carriage of 38.4% in eastern Madaba and lowest of 31.6% in northern Madaba, with an average carriage of all Madaba regions of 36.2% for both seasons as shown in [Table 3](#pone.0237247.t003){ref-type="table"}.

10.1371/journal.pone.0237247.t003

###### Rate of carriage of *Streptococcus pneumoniae* from Irbid and Madaba DCCs for both winter seasons of W2017-18 and W2018-19 with vaccine types and non-vaccine types.

![](pone.0237247.t003){#pone.0237247.t003g}

  City                 DCC        Carriage for both seasons   Vaccine types of PCV13   Non-Vaccine types                      
  -------------------- ---------- --------------------------- ------------------------ ------------------- --------- -------- ------
  Irbid                Alrazi     125/423                     29.6                     83/125              66.4      42/125   33.6
  Madaba               East       96/250                      38.4                     66/96               68.8      30/96    31.3
  West                 34/94      36.2                        22/34                    64.7                12/34     35.3     
  North                30/95      31.6                        16/30                    53.3                14/30     46.7     
  South                56/157     35.7                        41/56                    73.2                15/56     26.8     
  All DCCs of Madaba   216/596    36.2                        145/216                  67.1                71/216    32.9     
  Total                341/1019   33.5                        228/341                  66.9                113/341   33.1     

Resistance rates for penicillin, cefotaxime, clarithromycin, trimethoprim-sulfamethoxazole and tetracycline for Irbid were 92.8%, 0.8%, 79.2%, 91.2% and 48.8%, respectively. As a comparison, in all regions of Madaba resistance rates were 94.5%, 5.1%, 78.2%, 86.5% and 51.9%, respectively ([Fig 3](#pone.0237247.g003){ref-type="fig"}). Highest resistance rates for penicillin and tetracycline in both winter seasons was detected in the south of Madaba with rates 98.2% and 64.3%, respectively. For both seasons, trimethoprim-sulfamethoxazole resistance was highest in Irbid followed by eastern Madaba with resistance rates 91.2% and 87.6, respectively. Detailed numbers for [Fig 3](#pone.0237247.g003){ref-type="fig"} is available in supplementary file (see [S6 Table](#pone.0237247.s006){ref-type="supplementary-material"}). No resistance was noticed for the following antibiotics: Moxifloxacin, levofloxacin, telithromycin, vancomycin, ceftriaxone, tigecycline, rifampicin and linezolid.

![Carriage and resistance rates of *Streptococcus pneumoniae* isolates from eastern Irbid and all DCCs of Madaba for both winter seasons from October 2017 to End of March 2019.\
Abbreviations: PEN: Penicillin; AMOX: Amoxicillin; CETA: Cefotaxime; CEFU: Cefuroxime; CEPO: Cefpodoxime; CLA: Clarithromycin; CLI: Clindamycin; LEV: Levofloxacin; SXT: Trimethoprim-sulfamethoxazole; TET: Tetracycline; CHA: Chloramphenicole; I: Intermediate resistance; and R: Resistant.](pone.0237247.g003){#pone.0237247.g003}

Coverage of the pneumococcal conjugate vaccines PCV7, PCV10, and PCV13 for the 5 DCCs of the study showed highest coverage for the PCV13 in South of Madaba with coverage of 73.2% followed by eastern Irbid DCC with PCV13 coverage of 65.6% ([Fig 4](#pone.0237247.g004){ref-type="fig"}). However, coverage of available pneumococcal vaccines PCV7, PCV10 and PCV13 in Madaba regions showed highest coverage for both seasons in Madaba west with PCV7 and PCV10 coverage of 52.9% and 55.9%, respectively. Furtheremore, in Madaba regions coverage rates for PCV7, PCV10 and PCV13 in both winter seasons were 49.5%, 50.0%, and 65.3%, respectively. These coverage rates for both cities in both winter seasons were not significantly different (*P\> 0*.*05*).

![Coverage of the pneumococcal conjugate vaccines in each DCC for both winter seasons from October 2017-end of March 2019.](pone.0237247.g004){#pone.0237247.g004}

Predominant serotypes for both winter seasons for eastern Irbid city were: 19F, 23F, 6A, and 14 with rates 20.8%, 12%, 10.4%, 9.6%, and 7.2%, respectively. However, predominant serotypes for all Madaba regions in both winter seasons were 19F, 14, 6A, 23F and 6B with rates 24.5%, 7.4%, 6.9%, 6.5%, and 6.0%, respectively ([Table 4](#pone.0237247.t004){ref-type="table"}). In both cities, the predominant serotypes were all covered by the PCVs and were the same with different rates and rankings.

10.1371/journal.pone.0237247.t004

###### Percentage of serotypes recovered from all DCCs for both winter seasons.

![](pone.0237247.t004){#pone.0237247.t004g}

  Serotype                                  East (n = 96)   West (n = 34)   North (n = 30)   South (n = 56)   Madaba all DCCs (n = 216)   Eastern Irbid (n = 125)
  ----------------------------------------- --------------- --------------- ---------------- ---------------- --------------------------- -------------------------
  3                                         3.1             2.9             0                5.4              3.2                         0.8
  5                                         0               2.9             0                0                0.5                         0
  6A                                        4.2             2.9             13.3             10.7             6.9                         10.4
  6B                                        7.3             0               10               5.4              6                           9.6
  6C                                        1.0             0               0                0                0.5                         1.6
  7B                                        0               0               0                1.8              0.5                         0
  9N                                        0               0               3.3              0                0.5                         0
  9V                                        0               0               0                5.4              1.4                         0.8
  10A                                       1.0             0               3.3              1.8              1.4                         0.8
  11A                                       3.1             8.8             6.7              0                4.2                         3.2
  14                                        6.3             11.8            10               5.4              7.4                         7.2
  15A                                       0               2.9             0                0                0.5                         2.4
  15B                                       1.0             0               0                5.4              1.9                         2.4
  15C                                       1.0             8.8             0                3.6              2.8                         4
  16A                                       2.1             0               0                0                0.9                         0
  16F                                       1.0             0               0                0                0.5                         3.2
  17F                                       1.0             2.9             0                1.8              1.4                         0.8
  18C                                       3.1             0               0                7.1              3.2                         0.8
  19A                                       6.3             2.9             0                7.1              5.1                         3.2
  19F                                       28.1            26.5            13.3             23.2             24.5                        20.8
  23A                                       3.1             5.9             6.7              3.6              4.2                         1.6
  23F                                       5.2             14.7            6.7              3.6              6.5                         12
  [\#](#t004fn002){ref-type="table-fn"}23   4.2             0               0                0                1.9                         0.8
  28A                                       3.1             0               6.7              1.8              2.8                         0.8
  35A                                       1.0             0               0                0                0.5                         0.8
  NT                                        5.2             0               3.3              3.6              3.7                         1.6
  Mixed 14 & 6B                             1.0             0               0                0                0.5                         0
  Others                                    7.3             5.9             16.7             1.8              6.9                         10.8

\*Others: Serotypes belong to the group sera C, D, E, F, G, and not involved in the PCVs.

^\#^: Serogroup 23 was negative for all subtypes b, c and d.

Antibiotic resistance of vaccine serotypes was highest for penicillin with exception of the serotypes 3 and 5 ([Table 5](#pone.0237247.t005){ref-type="table"}). Furthermore antibiotic resistance of non-vaccine serotypes showed less resistance to the majority of antibiotics compared to vaccine types ([Table 5](#pone.0237247.t005){ref-type="table"}).

10.1371/journal.pone.0237247.t005

###### Antibiotic resistance for the vaccine serotypes and non-vaccine serotypes in both cities from October 2017 to the end of March 2019.

![](pone.0237247.t005){#pone.0237247.t005g}

  Serotype                                               \% PEN R   \% CLA R   \% CLI R   \% LEV R   \% SXT R   \% TET R   \% CHA R
  ------------------------------------------------------ ---------- ---------- ---------- ---------- ---------- ---------- ----------
  3 (n = 8)                                              37.5       12.5       0          0          37.5       12.5       0
  5 (n = 1)                                              0          0          0          0          100        0          0
  6A (n = 28)                                            96.4       92.9       32.1       0          78.6       32.1       0
  6B (n = 25)                                            100        96         72         0          96         76         8
  9V (n = 4)                                             100        100        0          0          100        100        0
  14 (n = 26)                                            100        100        92.3       0          92.3       34.6       0
  18C (n = 8)                                            100        0          0          0          87.5       2.4        0
  19A (n = 15)                                           100        93.3       6.7        0          93.3       13.3       0
  19F (n = 79)                                           100        98.7       91.1       1.3        91.1       88.6       0
  23F (n = 29)                                           100        82.8       34.5       3.4        100        48.3       13.8
  6C (n = 3)                                             66         100        66         0          66         100        0
  7B (n = 1)                                             0          100        100        0          0          100        0
  9N (n = 1)                                             100        100        100        0          100        100        0
  10A (n = 4)                                            100        0          0          0          100        25         0
  11A (n = 13)                                           100        69.2       7.7        0          100        7.7        0
  15A (n = 4)                                            100        100        100        0          100        100        0
  15B (n = 7)                                            100        100        14.3       0          100        85.7       0
  15C (n = 11)                                           100        90.9       0          0          100        90.9       0
  16A (n = 2)                                            50         0          0          0          50         0          0
  16F (n = 5)                                            80         60         20         0          100        40         0
  17F (n = 4)                                            100        25         0          25         75         0          0
  23A (n = 11)                                           100        72.7       36.4       0          72.7       27.3       0
  [\#](#t005fn002){ref-type="table-fn"}23 (n = 5)        100        20         0          20         60         0          0
  28A (n = 7)                                            85.7       85.7       42.9       0          85.7       42.9       0
  35A (n = 2)                                            100        50         50         0          100        0          0
  NT (n = 10)                                            80         80         10         10         90         50         0
  [\*](#t005fn003){ref-type="table-fn"}others (n = 28)   71.4       28.6       10.7       3.6        78.6       14.3       3.6

Abbreviations: Pen (Penicillin), CLA (Clarithromycin), CLI (Clindamycin), LEV (Levofloxacin), SXT (Trimethoprim-sulfamethoxazole), TET (Tetracycline), CHA (Chloramphenicole), R (Intermediate and high grade resistance), NT (non-typeable).

^\#^: serogroup 23 (was positive with the serogroup 23, but negative with type sera b, c and d).

\* Others (serotypes belong to the old serogroups C, D, E, F, G, and are non-vaccine types).

Discussion {#sec011}
==========

A total of 1019 children were enrolled in the study from 5 day care centers in two main cities of Jordan, namely eastern Irbid and Madaba. All of the children enrolled in this study had no history of previous vaccination with the pneumococcal conjugate vaccines, since families with low to middle income and cannot afford the cost of PCV at the private sector and that the PCV is not available in the National Immunization Program of the country. This is the largest number of the age group 2--4 years taken for studying the carriage of *S*. *pneumoniae* in two winter seasons of the years 2017--2018 and 2018--2019, which provides an insight into the state of pneumococcal carriage among this age group of healthy children attending day-care centers. Our results support the well established findings that acquisition of new strains of *S*. *pneumoniae* appears to be a seasonal phenomenon, with highest rates in the winter months \[[@pone.0237247.ref027], [@pone.0237247.ref028]\]. Furthermore, pneumococcal carriage proved to be more common among children 2 years of age with carriage rate of 70% as found in Norway \[[@pone.0237247.ref029]\]. There are variations of carriage between male and female genders among the DCCs for both seasons, in all regions of Madaba, males show a higher carriage rate than females with the highest rate in east Madaba, where 43.2% of males were carriers. Males at all Madaba DCCs prove to have higher carriage rates than females. This result was the opposite in Irbid, where female carriage rate was 31.0% compared to male carriage rate 28.2%. Few studies have been done on sex disparities in pneumococcal carriage or in pneumococcal invasive diseases, these disparities are thought to be due to biological and behavioral differences, which also vary with age \[[@pone.0237247.ref030]\]. Factors that contribute to high carriage rates in both cities are: low income, family members that smoke, and a high number of children per household as an important risk factor \[[@pone.0237247.ref004], [@pone.0237247.ref031]\]. Families with household more than 5 children showed carriage rate of 70.4% for Madaba, and 66.4% for eastern Irbid. The overall pneumococcal carriage prevalence in this study was 33.5% for all centers in both seasons. This is consistent with previous carriage study of healthy children not exposed to PCVs of the same age group conducted in Wadi Al Seer of Jordan (33.3%) \[[@pone.0237247.ref002]\]. For eastern Irbid, carriage rate for both winter seasons was 29.6%, which is significantly less than carriage rate of all Madaba DCCs in both seasons (36.2%) (P\< 0.05). Similar studies were performed in Jordan in other cities, and showed 55.1% for Wadi Al Seer \[[@pone.0237247.ref002]\], and 58.1% for Ajlun \[[@pone.0237247.ref005]\]. In both Wadi Al Seer and Ajlun, at least two to three samples were taken from each case, therefore a higher carriage rate was seen. This is also consistent with the study performed by Gray *et al*. 1980 \[[@pone.0237247.ref027]\], where more than one sample improved the isolation rate of *S*. *pneumoniae*. Overall in both cities, 65.4% of pneumococci belonged to PCV13 serotypes.

Due to limited serotyping data available from invasive pneumococcal disease in Jordan, monitoring serotype changes in pneumococcal carriage may be a practical way of assessing vaccine impact. The distribution of pneumococcal serotypes varied among regions of Madaba and eastern Irbid, ranging from 65.6% of serotypes carried by children in eastern Irbid belonging to PCV13 serotypes compared to 65.3% for children in Madaba. The proportion of circulating pneumococci with serotypes covered by the vaccine may vary among regions. The methodological differences in carriage studies and variations of carriage estimates may result from differences in climate, season or crowding which influence transmission \[[@pone.0237247.ref032]\]. It was found that children less than 5 years of age have more carriage of pneumococci than children 6--13 years of age \[[@pone.0237247.ref033]\].

High resistance rates were observed in this study, reaching 93.8% for penicillin, 78.6% for clarithromycin, 45.5% for clindamycin, 88.3% for co-trimoxazole, and 50.7% for tetracycline, for all DCCs in both cities and both seasons. These resistance rates were variable among DCCs and in each season. High consumption of antibiotics in the country, and a history of antibiotic consumption prior to their visits to the DCC could be the reason or contribute to increased resistant strains \[[@pone.0237247.ref034], [@pone.0237247.ref035]\]. Serotypes prevailing in Irbid were 19F (20.8%), 23F (12.0%), 6A (10.4%), and 6B (9.6%); whereas for Madaba were 19F (24.5%), 14 (7.4%), 6A (6.9%) and 23F (6.5%). In a study performed in China in 2008 for hospitalized pediatric patients younger than 14 years of age 94.7% of isolates were multidrug resistant, and 86.1% were of the PCV13 vaccine types, and that dominant serotypes were 19F (31.6%), 19A (19.8%), 23F (11.2%), 6A (9.1%), 14 (9.1%) and 15B (5.9%) \[[@pone.0237247.ref036]\].

Conclusions {#sec012}
===========

Continued surveillance of pneumococcal carriage, resistance and serotype distribution is essential, especially in countries where PCV is not included in the National Immunization program. In this study pneumococcal carriage rate and resistance rates were high taking into consideration that only one NP-swab was taken from each child. This was also true in households with more than 5 children. Resistance to antibiotics was highest for penicillin and trimethoprim-sulfamethoxazole and that the coverage rates of PCVs were high in some regions. Vaccine-serotype pneumococcal colonization continue to be common in children and proved to possess more resistance than non-vaccine serotypes. National vaccination using PCVs would likely prevent episodes of *S*. *pneumoniae* diseases and carriage together inhibiting the spread of antibiotic resistance. These data should help public health authorities in making future strategies to prevent pneumococcal carriage and resistance by choosing the appropriate PCV to cover most of serotypes rotating in the community.
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A major concern is the confusing nature of how the results presented. Many of the finer details can be summarized in the text referring to charts for support, highlight interesting differences for the reader to note. The numerous tables presenting the finer details can be presented in supplementary materials.
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Page 2, line 35: "DDC" should be defined on line 27.

Page 2, line 41: "PCV13 " should be defined.

Page 2, line 41: "PCV13 serotype coverage for Irbid was 65.6%, and for all regions of Madaba 65.3%." Since the rates are pretty much the same, for the abstract I suggest something similar to "Serotype coverage of the 13 valent pneumococcal vaccine (PCV13) was about 65% for both regions."

Page 2, line 42: "All vaccine serotypes isolated in this study included in the PCV13 showed penicillin resistance from 96.4% to 100% with exception to serotypes 3 and 5 in both cities." Suggest re-wording to: "Over 96% of isolates with PCV13 serotypes in this study were resistant to penicillin with the exception of serotypes 3 and 5."

Page 3, line 49: "... (S. pneumoniae)..." is not required here.

Page 6, line 118: Describe what the level of significance was, ie p\<0.05 using 2-tailed values.

Page 7, lines 135-138: If the differences between the two cities are not analyzed, the manuscript can be shortened by combining these data for both cities. Keep these details in table 1. Perhaps make table 1 a supplementary table?

Page 8 onward; page number missing from draft manuscript.

Line 151: Suggest using a chart to display this information and put Table 2 into supplementary material.

Line 165: Table 4 not included in draft. Again, maybe use a chart for this information instead of a table?

Line 171: If there is no statistical difference, just state as such and combine data for both cities. State detailed data only for the significant differences. The P\<0.05 indicates significance? This should be p\>0.05?

Line 172: I would suggest separating the monthly coverage variations of coverage from that of the antimicrobial resistance data. Keep the same data type together (ie. 1)monthly/seasonal trend of coverage; 2) AMR distributions geographically/temporal). Furthermore, perhaps the monthly trend of AMR is not needed, but present the just annual /regional differences if present?

Lines 200-203: Data in Tables 8-10 can be summarized to show the AMR results into a chart instead of the data from tables 6-7? Put detailed counts into supplementary material.

Line 221-223: Again, for easier reading, if there is no large or interesting differences, just make a general statement with the details.

Lines 232-240: Tables 8-10 seem to repeating data covered in previous tables? It is getting confusing as to what differences the read should be noting. Are tables 10-11 necessary? Can the data summarized and combined with previous data tables in a more efficient manner?

Lines 254- 278: Tables 11 -- 15 should be summarized into a figure if possible.

Line 283: Spelling error: "... studding..." ; "studying" ?

Reviewer \#2: Summary:

In this study the author has given statistics on the pneumococcal carriage rate in children of 2 to 4 years of age during winter season of 2017-2019 in Irbid and Madaba governorates of Jordan. Alongside, information regarding resistance, serotype distribution, and coverage of pneumococcal conjugate vaccines for the same study population is also provided.

Recommendations:

Accept after major revision. I support the potential publication of this manuscript due to its scientific interest. On the other hand, many aspects of the manuscript need to be extensively improved. I suggest the author to consider all of the following major remarks to improve the quality of the presentation of his work. To reiterate, the quality of the manuscript must be strengthened for it to be finally accepted.

1\) The use of English must greatly improve if the paper is to be published in PLOS ONE. The author needs to take inputs from similar papers in order to improve the overall presentation of his work.

2\) The "Introduction" section of the manuscript requires extensive revision. First of all, the author needs to expand the review of literature that is relevant to his study. Second, the aim of the study needs to be properly highlighted and justified. Instead of setting aim in the frame of a simplistic question (reviewer's personal point of view), I would suggest that the author should attempt to present the key objectives of his study with regards to what is currently known (i.e. literature), thus highlighting the added value of the paper.

3\) The inclusion criteria for the children must be clearly stated (for e.g., age group, previous vaccination history considerations and equal population from both the genders).

4\) Details of the demographic surveillance site with independent survey information (Socio-demographic characteristics) should be clearly described.

5\) There is no mention of the sampling procedures followed or details of the sample size calculation for this study.

6\) To my point of view, materials and method section of the manuscript is written in an amateurish way and does not match the quality standards for being publish in PLOS ONE. The description of the data collection, transportation, laboratory analysis, variable definition and data management & analysis is almost chaotic, while the use of terminology and language is too simplified. Probably a detail flowchart of methodology including the experiment results should be mentioned. The protocol for sampling from 1019 to 341 strain should be elaborated.

7\) To my view, this is not a proper presentation of the statistical results for a survey study. Again, information provided is very hard to follow. The author should consult similar papers to view how the data of a huge sampling study over 2 years should be properly presented and justified. For example, the data given in the manuscript are mainly in tabular form but can be more informative, if represented in the form of graphs or charts. Also, the result could be segmented in different sub-sections emphasizing on characteristics of the population, resistance and carriage rate and serotype distribution.

8\) It is surprising that the paper is owned by only one author, since an extensive work is performed and more than one centers are involved. I wonder how can we acknowledge others involved in the study.
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Response to reviewer 1

Comments Response

Major issue A major concern is the confusing nature of how the results presented. Many of the finer details can be summarized in the text referring to charts for support, highlight interesting differences for the reader to note. The numerous tables presenting the finer details can be presented in supplementary materials.

Some representative tables were changed into charts and figures and that their detailed tables were provided as supplementary material as requested

Minor issues

Page 2, line 35 "DCCs" should be defined on line 27 DCCs was defined in line 27 as first time mentioned in the text

Page 2, line 41 "PCV13 " should be defined Was changed to "the thirteen valent pneumococcal conjugate vaccine (PCV13)"

Page 2, line 41 PCV13 serotype coverage for Irbid was 65.6%, and for all regions of Madaba 65.3%." Since the rates are pretty much the same, for the abstract I suggest something similar to "Serotype coverage of the 13 valent pneumococcal vaccine (PCV13) was about 65% for both regions." Was done or changed as suggested to: Serotype coverage of the thirteen valent pneumococcal conjugate vaccine (PCV13) was about 65% for both regions

Page 2, line 42 "All vaccine serotypes isolated in this study included in the PCV13 showed penicillin resistance from 96.4% to 100% with exception to serotypes 3 and 5 in both cities." Suggest re-wording to: "Over 96% of isolates with PCV13 serotypes in this study were resistant to penicillin with the exception of serotypes 3 and 5." Was done or changed in the abstract as suggested to:

Over 96% of isolates with PCV13 serotypes in this study were resistant to penicillin with the exception of serotypes 3 and 5.

Page 3, line 49 "... (S. pneumoniae)..." is not required here

Done (deleted)

Page 6, line 118 Describe what the level of significance was, ie p\<0.05 using 2-tailed values Done as requested to:

Student t-test was considered for significant differences using 2-tailed values with the level of significance at p\<0.05.

Page 7, lines 135-138 If the differences between the two cities are not analysed, the manuscript can be shortened by combining these data for both cities. Keep these details in table 1. Perhaps make table 1 a supplementary table? Table 1 was changed according to the data available in lines 135-138, and Table 1 was changed to Table 1a with detailed number of NP-samples from each center and was put as supplementary table

Page 8 onward page number missing from draft manuscript Page numbers were added

Line 151 Suggest using a chart to display this information and put Table 2 into supplementary material. A chart as Fig 1. was made to display table 2, and table 2 was put as supplementary material as suggested

Line 165 Table 4 not included in draft. Again, maybe use a chart for this information instead of a table? Table 4 was inserted as Fig 2. As the Table 4 was put as supplementary to the figure

Line 171 If there is no statistical difference, just state as such and combine data for both cities. State detailed data only for the significant differences. The P\<0.05 indicates significance? This should be p\>0.05? This is true, was changed accordingly

Line 172 I would suggest separating the monthly coverage variations of coverage from that of the antimicrobial resistance data. Keep the same data type together (ie. 1) monthly/seasonal trend of coverage; 2) AMR distributions geographically/temporal). Furthermore, perhaps the monthly trend of AMR is not needed, but present the just annual /regional differences if present? Done as suggested, so that in table 5 was only for the coverage rates on monthly basis for both cities, and in table 6 was for the resistance rates for both cities on monthly basis (Annual rates was shown in other table. Figure 3 and 4 were set for these data and tables 5 and 6 will be as supplementary to show the difference between the two cities

Lines 200-203 Data in Tables 8-10 can be summarized to show the AMR results into a chart instead of the data from tables 6-7? Put detailed counts into supplementary material.

Tables 8-10 were summarized in one table to avoid repetition of data. Figure 5 was made and the table was set as supplementary as requested

Line 221-223 Again, for easier reading, if there is no large or interesting differences, just make a general statement with the details. Done as requested

Lines 232-240 Tables 8-10 seem to repeating data covered in previous tables. It is getting confusing as to what differences the read should be noting Tables were restructured, so that no repeated data are available anymore

Lines 232-240 Are tables 10-11 necessary? Can the data summarized and combined with previous data tables in a more efficient manner? Data for tables 8 and 9 were partly fused into table 10 to avoid repetition of data. Table 10 was then changed into chart and the table was left as supplementary material

Lines 254- 278 Tables 11 -- 15 should be summarized into a figure if possible For these tables again to avoid repetition of data, tables 11 and 13 were put in one table, table 12 was deleted, and table 14 and 15 were put in one table. The number of the serotypes and data are huge, so that they could not fit in a chart, hoping you will be ok with this solution

Line 283 Spelling error: "... studding..." ; "studying" ? Spelling error corrected "Studying"

Response to reviewer 2

Major aspects Comments Response

Point 1 The use of English must greatly improve if the paper is to be published in PLOS ONE. The author needs to take inputs from similar papers in order to improve the overall presentation of his work. The English was improved by a native speaker from England, and more input was inserted from similar papers

Point 2 The "Introduction" section of the manuscript requires extensive revision. First, the author needs to expand the review of literature that is relevant to his study. Second, the aim of the study needs to be properly highlighted and justified. Instead of setting aim in the frame of a simplistic question (reviewer's personal point of view), I would suggest that the author should attempt to present the key objectives of his study with regards to what is currently known (i.e. literature), thus highlighting the added value of the paper. The introduction was extended with more literature. Regarding the aims of the study were highlighted at the end of the introduction. Since the study group are well known to be in other countries with the highest carriage, and that the DCCs chosen are all in rural areas visited from families mostly with low income and cannot afford the cost of vaccination with the available PCVs. An important issue here is to show the resulted serotypes with more rates belonging to the PCVs harbouring high rates of resistance

Point 3 The inclusion criteria for the children must be clearly stated (for e.g., age group, previous vaccination history considerations and equal population from both the genders). The age group for this study is 2-4 years was chosen by the funding agency, since it is well known worldwide with high carriage rate and according to the world population review reports, this age group count 673.8 thousand or almost 5% of the total population. All children of this study did not have any previous history of PCV vaccination, and this was included in the text.

Point 4 Details of the demographic surveillance site with independent survey information (Socio-demographic characteristics) should be clearly described. Regarding demographic surveillance and the socio-economic characteristics. Age group is fixed in the study. Children belong to families with low to middle income and all DCCs are in rural areas

Point 5 There is no mention of the sampling procedures followed or details of the sample size calculation for this study. Regarding sample size. All possible children of age 2-4 years visiting the chosen DCCs in the period of the study were subject to give NP-swabs. Number of NP-swabs was supposed to be 700 but was increased to 1019 at the end of the study to involve most children of this age group in this study

Point 6 To my point of view, materials and method section of the manuscript is written in an amateurish way and does not match the quality standards for being publish in PLOS ONE. The description of the data collection, transportation, laboratory analysis, variable definition and data management & analysis is almost chaotic, while the use of terminology and language is too simplified. Probably a detail flowchart of methodology including the experiment results should be mentioned. The protocol for sampling from 1019 to 341 strain should be elaborated.

The section Materials and Methods was completely restructured to meet the standards of PLOS ONE as requested

Point 7 To my view, this is not a proper presentation of the statistical results for a survey study. Again, information provided is very hard to follow. The author should consult similar papers to view how the data of a huge sampling study over 2 years should be properly presented and justified. For example, the data given in the manuscript are mainly in tabular form but can be more informative, if represented in the form of graphs or charts. Also, the result could be segmented in different sub-sections emphasizing on characteristics of the population, resistance and carriage rate and serotype distribution. Most of tabular results were changed into charts or figures for better understanding and that repeated results were deleted. Most figures were included in the manuscript and some of the tables were left as supplementary for proper and more informative presentation. Segmentation of the results is also done for each characteristic alone

Point 8 It is surprising that the paper is owned by only one author, since an extensive work is performed and more than one centers are involved. I wonder how can we acknowledge others involved in the study. All participants in this study project have received monthly salaries for sample collection and transfer, and have no impact in writing or data analysis in the paper. Furthermore, Only one paediatric in Jordan have published on pneumococci in addition to me. Another point is that my experience at the National Reference Center for Streptococci in Germany has enabled me to establish a new lab at the German Jordanian University and do most of the work independently.
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Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 30 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.
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Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This revised manuscript attempts to improve the presentation of data concerning pneumococcal carriage rates in two cites of Jordan among non-immunized children. Although the paper contains valuable information adding to the knowledge of global dissemination of pneumococcal serotypes and antimicrobial resistance, the author is still having challenges presenting the data in a clear, concise and intelligible manner.

Minor issues:

There are still some grammatical and awkward English translation issues that will need to be addressed by the editor prior to final publication.

Lines 138-144: Some antibiotics are capitalized which should be changed to lower case.

Major Issues:

Line 176 - Figure 1: There seems to be two series of data on the x-axis labelled the same: The first two series "%male carriers 17-18" and "%female carriers 17-18" are labelled the same as series 5 and 6.

Line 185 : Remove table 2.

Figure 3: remove columns for % PCV10 and %PCV7. Keep only %PCV13 and %Carriage.

Figure 4: Should use x-axis as the temporal variable.

Keep Figures 5 and 6, remove figures 1 and 2.

Reviewer \#2: This paper experimentally demonstrates that a resistance and carriage rates among the age group 2 to 4 years for a period of two years, reached an alarming rate especially among vaccine types and propose that it can be controlled by pneumococcal conjugate vaccination strategies. The authors have clarified almost all of the questions raised in the previous review. However, the resolutions of the graphs provided could be improved. Overall, this version of manuscript has been sufficiently improved.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Thank you for the valid feedback received on Monday 15th of June 2020. Below, please find the responses to the reviewers' comments.

Response to reviewer 1

Comments Response

Minor issues:

Lines 138-144: Some antibiotics are capitalized which should be changed to lower case.

Capitalized antibiotics were changed into small letters as requested

Major issues:

Line 176 - Figure 1: There seems to be two series of data on the x-axis labelled the same: The first two series "%male carriers 17-18" and "%female carriers 17-18" are labelled the same as series 5 and 6.

Figures 1 and 2 were removed as requested in the last point and kept the tables as supplementary material

Line 185 : Remove table 2. Removed

Figure 3: Remove columns for % PCV10 and %PCV7. Keep only %PCV13 and % Carriage Data for PCV7 and PCV10 were removed and kept only % carriage and % PCV13 coverage as requested

Figure 4: Should use x-axis as the temporal variable. Done as requested

Keep Figures 5 and 6, remove figures 1 and 2. Keep Figures 5 and 6, remove figures 1 and 2. Figures 1 and 2 were removed as requested and kept Figures 5 and 6. The manuscript text was changed accordingly and kept only the supplementary tables for these figures

Response to reviewer 2 This paper experimentally demonstrates that a resistance and carriage rates among the age group 2 to 4 years for a period of two years, reached an alarming rate especially among vaccine types and propose that it can be controlled by pneumococcal conjugate vaccination strategies. The authors have clarified almost all of the questions raised in the previous review. However, the resolutions of the graphs provided could be improved. Overall, this version of manuscript has been sufficiently improved. Much appreciated for the response. Better resolution of the figures was done as requested
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Submitted filename: Response to reviewers.docx
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Click here for additional data file.
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An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.
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